Dietary and serum advanced glycation end-products and clinical outcomes in breast cancer

Biochim Biophys Acta Rev Cancer. 2024 Jan;1879(1):188995. doi: 10.1016/j.bbcan.2023.188995. Epub 2023 Oct 6.

Abstract

One in five women with breast cancer will relapse despite ideal treatment. Body weight and physical activity are strongly associated with recurrence risk, thus lifestyle modification is an attractive strategy to improve prognosis. Trials of dietary modification in breast cancer are promising but the role of specific diets is unclear, as is whether high-quality diet without weight loss can impact prognosis. Advanced glycation end-products (AGEs) are compounds produced in the body during sugar metabolism. Exogenous AGEs, such as those found in food, combined with endogenous AGEs, make up the total body AGE load. AGEs deposit in tissues over time impacting cell signaling pathways and altering protein functions. AGEs can be measured or estimated in the diet and measured in blood through their metabolites. Studies demonstrate an association between AGEs and breast cancer risk and prognosis. Here, we review the clinical data on dietary and serum AGEs in breast cancer.

Keywords: Advanced glycation end-products; Biomarker; Breast cancer; Diet; Lifestyle.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms* / drug therapy
  • Diet
  • Female
  • Glycation End Products, Advanced* / metabolism
  • Glycation End Products, Advanced* / therapeutic use
  • Humans
  • Maillard Reaction

Substances

  • Glycation End Products, Advanced